ZURICH/LONDON, March 26 (Reuters) - Novartis AG (NOVN.VX: Quote, Profile , Research) and Bayer AG (BAYG.DE: Quote, Profile , Research) have settled a dispute over multiple sclerosis drug Betaseron in a deal that gives Bayer full control of the product while letting Novartis launch a version in 2009.
